Faecal microbiota transplantation: a sui generis biological drug, not a tissue.
Identifieur interne : 003984 ( Main/Merge ); précédent : 003983; suivant : 003985Faecal microbiota transplantation: a sui generis biological drug, not a tissue.
Auteurs : F. Megerlin [France] ; E. Fouassier [France] ; R. Lopert [Australie] ; P. Bourlioux [France]Source :
- Annales pharmaceutiques francaises [ 0003-4509 ] ; 2014.
Descripteurs français
- KwdFr :
- MESH :
- législation et jurisprudence : Transplantation de tissu.
- microbiologie : Fèces.
- Animaux, Humains, Infections à Clostridium.
English descriptors
- KwdEn :
- MESH :
- legislation & jurisprudence : Tissue Transplantation.
- microbiology : Feces.
- therapy : Clostridium Infections.
- Animals, Humans.
Abstract
Responding to Smith et al. (Nature, 2014), this paper argues that for medical use, faecal microbiota transplantation (FMT) should be considered a sui generis biological drug, rather than a tissue. Smith and colleagues' thesis is based on possible undesirable economic consequences of this designation--not on its scientific and conceptual basis. The faecal transplant (including gut microbiota, metabolites, mucus, human cells, viruses, fungi, etc.) is not a tissue; it is of topographic--not cellular--human origin. We consider the donor a bioreactor, producing the faecal substrate of therapeutic interest. The debate is of singular importance as the FDA considers FMT a drug and released a new guidance for public consultation in February 2014, whereas to date the European Medicines Agency has not promulgated its position. The UK's National Institute for Heath and Care Excellence does not consider FMT to involve the transplantation of body tissue, and in March 2014 the French regulatory agency ANSM expressly declared it to be a drug. As FM is a complex and highly variable admixture, its components cannot be completely characterized, and to date, compositional quality cannot be assessed. We consider FMT to be a sui generis biologic drug, albeit one prepared with unconventional raw material under microbiologic control. The possibility of associating identified bacterial species with particular diseases and cultivating selected bacteria of therapeutic interest would certainly define a second generation of microbiome therapeutics, but is still speculative.
DOI: 10.1016/j.pharma.2014.04.008
PubMed: 24997882
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003605
- to stream PubMed, to step Curation: 003492
- to stream PubMed, to step Checkpoint: 003492
- to stream Ncbi, to step Merge: 001C03
- to stream Ncbi, to step Curation: 001C03
- to stream Ncbi, to step Checkpoint: 001C03
Links to Exploration step
pubmed:24997882Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Faecal microbiota transplantation: a sui generis biological drug, not a tissue.</title><author><name sortKey="Megerlin, F" sort="Megerlin, F" uniqKey="Megerlin F" first="F" last="Megerlin">F. Megerlin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Health Law and Economics, School of Pharmacy, University Paris Descartes, 4, avenue de l'Observatoire, 75006 Paris, France; Berkeley Center for Health Technology, University of California, Berkeley, CA, United States; GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France. Electronic address: francis.megerlin@parisdescartes.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Health Law and Economics, School of Pharmacy, University Paris Descartes, 4, avenue de l'Observatoire, 75006 Paris, France; Berkeley Center for Health Technology, University of California, Berkeley, CA, United States; GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Fouassier, E" sort="Fouassier, E" uniqKey="Fouassier E" first="E" last="Fouassier">E. Fouassier</name><affiliation wicri:level="1"><nlm:affiliation>GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author><author><name sortKey="Lopert, R" sort="Lopert, R" uniqKey="Lopert R" first="R" last="Lopert">R. Lopert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Health Policy, Milken Institute School of Public Health, George Washington University, Washington DC, 950 New Hampshire Avenue, NW 7th Floor, Washington, DC 20052 United States; LWC Health Pty Ltd, Canberra, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Health Policy, Milken Institute School of Public Health, George Washington University, Washington DC, 950 New Hampshire Avenue, NW 7th Floor, Washington, DC 20052 United States; LWC Health Pty Ltd, Canberra</wicri:regionArea><wicri:noRegion>Canberra</wicri:noRegion></affiliation></author><author><name sortKey="Bourlioux, P" sort="Bourlioux, P" uniqKey="Bourlioux P" first="P" last="Bourlioux">P. Bourlioux</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Pharmacy, University of Paris Sud, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Microbiology, School of Pharmacy, University of Paris Sud, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24997882</idno><idno type="pmid">24997882</idno><idno type="doi">10.1016/j.pharma.2014.04.008</idno><idno type="wicri:Area/PubMed/Corpus">003605</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003605</idno><idno type="wicri:Area/PubMed/Curation">003492</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003492</idno><idno type="wicri:Area/PubMed/Checkpoint">003492</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003492</idno><idno type="wicri:Area/Ncbi/Merge">001C03</idno><idno type="wicri:Area/Ncbi/Curation">001C03</idno><idno type="wicri:Area/Ncbi/Checkpoint">001C03</idno><idno type="wicri:doubleKey">0003-4509:2014:Megerlin F:faecal:microbiota:transplantation</idno><idno type="wicri:Area/Main/Merge">003984</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Faecal microbiota transplantation: a sui generis biological drug, not a tissue.</title><author><name sortKey="Megerlin, F" sort="Megerlin, F" uniqKey="Megerlin F" first="F" last="Megerlin">F. Megerlin</name><affiliation wicri:level="3"><nlm:affiliation>Department of Health Law and Economics, School of Pharmacy, University Paris Descartes, 4, avenue de l'Observatoire, 75006 Paris, France; Berkeley Center for Health Technology, University of California, Berkeley, CA, United States; GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France. Electronic address: francis.megerlin@parisdescartes.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Health Law and Economics, School of Pharmacy, University Paris Descartes, 4, avenue de l'Observatoire, 75006 Paris, France; Berkeley Center for Health Technology, University of California, Berkeley, CA, United States; GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Fouassier, E" sort="Fouassier, E" uniqKey="Fouassier E" first="E" last="Fouassier">E. Fouassier</name><affiliation wicri:level="3"><nlm:affiliation>GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GRADES University of Paris Sud, 5, rue Jean-Baptiste-Clément, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Lopert, R" sort="Lopert, R" uniqKey="Lopert R" first="R" last="Lopert">R. Lopert</name><affiliation wicri:level="1"><nlm:affiliation>Department of Health Policy, Milken Institute School of Public Health, George Washington University, Washington DC, 950 New Hampshire Avenue, NW 7th Floor, Washington, DC 20052 United States; LWC Health Pty Ltd, Canberra, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Health Policy, Milken Institute School of Public Health, George Washington University, Washington DC, 950 New Hampshire Avenue, NW 7th Floor, Washington, DC 20052 United States; LWC Health Pty Ltd, Canberra</wicri:regionArea><wicri:noRegion>Canberra</wicri:noRegion></affiliation></author><author><name sortKey="Bourlioux, P" sort="Bourlioux, P" uniqKey="Bourlioux P" first="P" last="Bourlioux">P. Bourlioux</name><affiliation wicri:level="1"><nlm:affiliation>Department of Microbiology, School of Pharmacy, University of Paris Sud, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Microbiology, School of Pharmacy, University of Paris Sud, 92296 Châtenay-Malabry cedex, France; Académie nationale de pharmacie, 4, avenue de l'Observatoire, 75006 Paris</wicri:regionArea><wicri:noRegion>75006 Paris</wicri:noRegion><placeName><settlement type="city">Paris</settlement><region type="région" nuts="2">Île-de-France</region></placeName></affiliation></author></analytic><series><title level="j">Annales pharmaceutiques francaises</title><idno type="ISSN">0003-4509</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Clostridium Infections (therapy)</term><term>Feces (microbiology)</term><term>Humans</term><term>Tissue Transplantation (legislation & jurisprudence)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Fèces (microbiologie)</term><term>Humains</term><term>Infections à Clostridium ()</term><term>Transplantation de tissu (législation et jurisprudence)</term></keywords><keywords scheme="MESH" qualifier="legislation & jurisprudence" xml:lang="en"><term>Tissue Transplantation</term></keywords><keywords scheme="MESH" qualifier="législation et jurisprudence" xml:lang="fr"><term>Transplantation de tissu</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Fèces</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Feces</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Clostridium Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Infections à Clostridium</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Responding to Smith et al. (Nature, 2014), this paper argues that for medical use, faecal microbiota transplantation (FMT) should be considered a sui generis biological drug, rather than a tissue. Smith and colleagues' thesis is based on possible undesirable economic consequences of this designation--not on its scientific and conceptual basis. The faecal transplant (including gut microbiota, metabolites, mucus, human cells, viruses, fungi, etc.) is not a tissue; it is of topographic--not cellular--human origin. We consider the donor a bioreactor, producing the faecal substrate of therapeutic interest. The debate is of singular importance as the FDA considers FMT a drug and released a new guidance for public consultation in February 2014, whereas to date the European Medicines Agency has not promulgated its position. The UK's National Institute for Heath and Care Excellence does not consider FMT to involve the transplantation of body tissue, and in March 2014 the French regulatory agency ANSM expressly declared it to be a drug. As FM is a complex and highly variable admixture, its components cannot be completely characterized, and to date, compositional quality cannot be assessed. We consider FMT to be a sui generis biologic drug, albeit one prepared with unconventional raw material under microbiologic control. The possibility of associating identified bacterial species with particular diseases and cultivating selected bacteria of therapeutic interest would certainly define a second generation of microbiome therapeutics, but is still speculative.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003984 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003984 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:24997882
|texte= Faecal microbiota transplantation: a sui generis biological drug, not a tissue.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:24997882" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |